Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Advanced Solid Tumor × talazoparib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Breast Neoplasms 9 Prostatic Neoplasms 5 Neoplasms 4 Neoplasm Metastasis 4 Advanced Solid Tumors 4 Leukemia, Myeloid, Acute 3 Triple Negative Breast Neoplasms 2 Pancreatic Neoplasms 2 Ovarian Neoplasms 2 Solid Tumor 1 Small Cell Lung Carcinoma 1 Sarcoma, Ewing 1 Recurrent Squamous Cell Lung Carcinoma 1 Neuroectodermal Tumors, Primitive, Peripheral 1 Myelodysplastic Syndromes 1 Lymphoma, Mantle-Cell 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Kidney Neoplasms 1 Glioma 1 Glioblastoma 1 Fanconi Anemia, Complementation Group D1 1 Fallopian Tube Neoplasms 1 Colorectal Neoplasms 1 Childhood Solid Tumors 1 Central Nervous System Neoplasms 1 Carcinoma, Renal Cell 1 Carcinoma, Ovarian Epithelial 1 Breast Adenocarcinoma 1 Advanced Solid Tumor 1 Advanced Ovarian Cancer 1

Interventions

toripalimab 5 Injections 4 tislelizumab 3 sintilimab 3 pembrolizumab 2 glumetinib 2 apatinib 2 PM 01183 2 Midazolam 2 Gemcitabine 2 Drug Therapy 2 Digoxin 2 Bupropion 2 talazoparib 1 spartalizumab 1 sonidegib 1 sitravatinib 1 serabelisib 1 rucaparib 1 repaglinide 1 penpulimab 1 palbociclib 1 lenvatinib 1 fluzoparib 1 entrectinib 1 capmatinib 1 camrelizumab 1 cabazitaxel 1 binimetinib 1 berzosertib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04497116 2025-10-21

TRESR

Repare Therapeutics

Phase 1/2 Completed

276 enrolled 33 charts

Other solid neoplasm

Advanced Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡